Clinical Trials Browser

Phase 1 × INDUSTRY × bivatuzumab mertansine × Clear all

NCT02254005 2023-10-24

Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer

Phase 1 Completed

Breast Neoplasms

NCT02254018 2023-10-24

Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck

Phase 1 Completed

Head and Neck Neoplasms

NCT02254031 2023-10-24

Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT02254044 2014-10-01

Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus

Phase 1 Terminated

Carcinoma, Squamous Cell